Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Predicting who is likely or unlikely to respond to checkpoint inhibitors remains a focus for researchers.
Targeted therapies and immunotherapies may be effective against the bone metastases that grow from primary prostate cancers.
“What the study means, and what we show, is that location or income should not hinder the use of these [drugs].”
Life is capricious — our plans go awry, our way is confounded, our destiny indeterminate. And yet, we go on because we choose to.
For decades, researchers have sought to better understand the mechanisms that govern metastasis.
Centura Health Corp. fired a geriatrician who had planned to help a patient with terminal cancer legally end his life at his Colorado home.
The study’s findings open a window for very early detection of the disease and could help identify those who need more aggressive treatment.
A first-of-its-kind rapid autopsy program helps reveal the deadly disease’s potential vulnerabilities.
A 2016 study found that just 5% of cancer patients understood their prognoses well enough to make informed decisions about their care.
At times I feel like I’m flapping around in a panic, not really knowing what to do, wasting time worrying and not really achieving anything!
The results of the study are huge and challenge the standard of care.
Researchers analyzed treatment patterns among people diagnosed with four major forms of metastatic cancer.
More patients with metastatic cancer and bone metastases are living longer today, so the need to address bone pain has increased.
Gaby Kressly, now in her early 80s, was diagnosed with ovarian cancer in 2016.
Priscilla K. Brastianos, MD, is driven to find cures.
Clinical trials often exclude key patient populations, including children and people living with HIV or hepatitis B or C.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.